Ephedra seizure
This article was originally published in The Tan Sheet
Executive Summary
U.S. Marshals seized 200 cases of finished ephedra product, 200 boxes of bulk tablets and nine 25 kilo drums of ephedrine alkaloid raw material thus far in enforcement action against Hi-Tech Pharmaceuticals, FDA announces Feb. 24. The products are labeled as containing 25 mg of ephedrine alkaloids per tablet and are marketed under the names Stimerex-ES, Lipodrene and Betadrene, the agency states. The U.S. Attorney's Office for the Northern District of Georgia also has filed a complaint for forfeiture against the firm; the product is being seized from Hi-Tech's Norcross, Ga. facility. The enforcement action will prevent approximately $3 mil. worth of ephedra products marketed by the company from reaching consumers, FDA adds. High-Tech also faced seizure of its ephedra products by FDA in January (1"The Tan Sheet" Jan. 16, 2005, p. 10). The firm filed a September lawsuit seeking to prevent the agency from enforcing its 2004 ephedra ban, and FDA recently moved to dismiss the case...
You may also be interested in...
Hi-Tech Pharmaceuticals Indicted For Online “Generic” Drug Enterprise
A federal grand jury has indicted Hi-Tech Pharmaceuticals and 11 individuals on multiple felony charges for allegedly selling adulterated and unapproved new drugs via the Internet, the Drug Enforcement Agency announced Sept. 20
Firm Flouting Ephedra Ban Faces Product Seizure By U.S. Marshals
An FDA-prompted seizure of ephedra products could make it more likely Hi-Tech pharmaceuticals' suit against the FDA over the ephedra ban will go to court, according to the firm
FDA’s New Dataset Aims To Assist Labs In Assessing Medical Device Biocompatibility
The US FDA’s device center has unveiled a new public dataset designed to assist chemistry laboratories in ensuring the robustness of chemical characterization methods used to assess the biocompatibility of medical devices.